Human/Mouse LRRN1/NLRR-1 Antibody

LRRN1/NLRR‑1 in Embryonic Mouse Somites. LRRN1/NLRR-1 was detected in immersion fixed frozen sections of embryonic mouse somites (E9.5) using 10 µg/mL Sheep Anti-Human LRRN1/NLRR-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4990) overnight at 4 °C. Tissue was stained with the NorthernLights™ 557-conjugated Anti-Sheep IgG Secondary Antibody (red; Catalog # NL010) and counterstained with DAPI (blue). View our protocol for Fluorescent IHC Staining of Frozen Tissue Sections.

Detection of LRRN1/NLRR-1 by Western Blot N1mAbs potentiates EGFR inhibitor-induced growth suppression. (A) NLRR1-stably expressing SH-SY5Y cells were treated with N1mAb 281 (25 μg/ml) and different concentrations of AG1478 (AG) for 72 h Data are represented as mean ± SD. Quantification of cell proliferation was performed by WST-8 assays. Data were normalized to the results for untreated cells and represented as percentage of control (mean ± SD). (B) AG1478-resistant A549 cells were treated with N1mAb 281 and different concentrations of AG1478 for 72 h (C) NLRR1-stably expressing SH-SY5Y cells were starved and treated with N1mAb 240 or 281 at 25 μg/ml for 3 h, followed by EGF treatment at the indicated concentration for 10 min. Cell lysates were subjected to western blot analyses. Arrowheads, glycosylated NLRR1. (D) MCF7 cells overexpressing NLRR1 were starved and treated with N1mAb 281 at 25 μg/ml for 3 h, followed by EGF treatment (1 ng/ml) for 10 min. The cell lysates were subjected to western blot analyses. (E) To check the effect of the long-term treatment of N1mAbs, SK-N-BE cells were incubated with N1mAbs (30 μg/ml) for 7 days with medium change every 2 days, and the cell lysates were subjected to western blot analyses. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/34277416), licensed under a CC-BY license. Not internally tested by R&D Systems.